Drug Trial Radar · NCT00460317
MONET1-MOtesanib NSCLC Efficacy and Tolerability Study
Last checked: Nov 19, 2026Latest source record: Sep 7, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,450
Actual
Start
Jul 2007
Primary completion
Mar 2011
Study completion Aug 2013
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- Collaborators
- Takeda
- First posted
- Apr 13, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine if treatment with AMG 706 (motesanib diphosphate) in combination with paclitaxel and carboplatin improves overall survival compared to treatment with placebo in combination with paclitaxel and carboplatin in subjects with advanced non-squamous NSCLC and in subjects with adenocarcinoma histology (adenocarcinoma subpopulation).
Conditions
- Non-Small Cell Lung Cancer
Interventions
AMG 706Drug
125 mg QD orally every day
placeboDrug
125 mg QD orally every day
paclitaxelDrug
200mg/m2 on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
carboplatinDrug
AUC of 600mg/mL x min by Calvert formula on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival time. Time from randomization to death. Subjects who have not died while on study or are lost to follow up will be censored at their last contact date.Time frame: Not able to be measured
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.